Key Points Systemic Light Chain Amyloidosis Immunoglobulin light chain (AL) amyloidosis
is a rare disease that occurs when a plasma cell disorder produces monoclonal light chains …

AL amyloidosis is caused by the excessive production of nonfunctional immunoglobulins,
leading to the formation of amyloid fibrils that damage vital organs, especially the heart and …

Relapse after ASCT is an important factor affecting the long-term prognosis of patients with
AL amyloidosis. However, the risk factors of relapse are unknown and there are limited …

The primary goal of the initial treatment in systemic light chain amyloidosis is to obtain a
rapid and profound haematological response as safely as possible, coupled with supportive …

Light chain (AL) amyloidosis is an uncommon clinical manifestation of Waldenström
macroglobulinemia (WM), an IgM-secreting lymphoplasmacytic lymphoma characterized by …

The role of high-dose melphalan-autologous hematopoietic cell transplantation (HDM-
AHCT) in systemic immunoglobulin light chain (AL) amyloidosis has undergone renewed …

Light chain (AL) amyloidosis is a plasma cell disorder distinguished from multiple myeloma
(MM) by the degree of organ involvement due to tissue deposition of misfolded proteins …

Amyloid fibril deposition causes progressive tissue damage and organ failure in the
systemic amyloid diseases, and therapies that suppress aggregation lead to clinical benefit …

Systemic Light chain (AL) amyloidosis is a monoclonal plasma cell disease characterized by
the deposition of amyloidogenic monoclonal light chain fragments in organs, causing their …

Patients with systemic light chain (AL) amyloidosis undergoing treatment with high-dose
melphalan and autologous stem cell transplantation (HDM/SCT) may develop renal and …